Novartis AG NVS
Set alert
At close · Oct 30
After hours · Oct 30, 4:22 PM ET
- YTD
- +16.62%
- 1 year
- +31.14%
- Open
- 162.53
- Prev close
- 161.10
- Mkt cap
- 303.67B
- Vol
- 3.15M
- Avg vol
- 2.02M
- EPS
- 5.24
- P/E
- 30.69
- Div yield
- 2.94%
More statistics
- Low
- 160.42
- High
- 164.06
- Forward P/E
- 16.23
- Beta
- 0.47
- Short ratio
- 3.01
- Inst. own
- 7.31%
- Dividend
- 4.74
- Ex-div date
- Mar 10, 2026
- Earnings
- Feb 3, 2027
- 50-d avg
- 148.31
- 200-d avg
- 151.74
- 1y target
- 155.29
5D chart
Events in this range
- Oct 27, 2026Earnings: 2.46; estimate 2.25; surprise 9.33%
- Oct 30, 2026Downgrade: Deutsche Bank · Hold → Sell
Signals (129)
| Name | Time | Ago |
|---|---|---|
| RSI: Oversold | Oct 30, 3:50 PM | 1 day ago |
| RSI: Oversold | Oct 30, 3:35 PM | 1 day ago |
| RSI: Oversold | Oct 30, 3:25 PM | 1 day ago |
| RSI: Oversold | Oct 30, 3:15 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 2:40 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:10 PM | 1 day ago |
| SMA: Bullish | Oct 30, 1:50 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 1:50 PM | 1 day ago |
| SMA: Bearish | Oct 30, 1:45 PM | 1 day ago |
| SMA: Bullish | Oct 30, 1:30 PM | 1 day ago |
| SMA: Bearish | Oct 30, 12:50 PM | 1 day ago |
| SMA: Bullish | Oct 30, 12:35 PM | 1 day ago |
| SMA: Bearish | Oct 30, 12:25 PM | 1 day ago |
| SMA: Bearish | Oct 30, 12:25 PM | 1 day ago |
| SMA: Bullish | Oct 30, 12:05 PM | 1 day ago |
| SMA: Bullish | Oct 30, 12:05 PM | 1 day ago |
| SMA: Bearish | Oct 30, 11:40 AM | 1 day ago |
| SMA: Bearish | Oct 30, 11:40 AM | 1 day ago |
| SMA: Bullish | Oct 30, 10:50 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 10:15 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:00 AM | 2 days ago |
| RSI: Overbought | Oct 30, 9:30 AM | 2 days ago |
| RSI: Overbought | Oct 29, 3:25 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:00 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:45 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:40 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:15 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:10 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:20 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:05 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:50 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:45 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:40 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:35 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:25 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:25 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:10 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:00 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:40 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:25 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:10 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:50 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:45 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:40 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:20 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 3:00 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:55 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:45 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:40 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 12:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 3 days ago |
| RSI: Oversold | Oct 28, 12:25 PM | 3 days ago |
| SMA: Bearish | Oct 28, 11:40 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 11:25 AM | 3 days ago |
| SMA: Bullish | Oct 28, 11:15 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:05 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:00 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:35 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:25 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 4 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 4 days ago |
| RSI: Overbought | Oct 27, 3:45 PM | 4 days ago |
| RSI: Overbought | Oct 27, 3:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:20 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:00 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:40 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:30 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:20 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 2:20 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 12:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:25 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:15 PM | 4 days ago |
| SMA: Bearish | Oct 27, 11:45 AM | 4 days ago |
| SMA: Bullish | Oct 27, 11:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:20 AM | 4 days ago |
| SMA: Bullish | Oct 27, 11:05 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:55 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:50 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 10:25 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:15 AM | 5 days ago |
| RSI: Overbought | Oct 27, 9:50 AM | 5 days ago |
| RSI: Overbought | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:55 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 2:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 2:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:15 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:55 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 12:40 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:05 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:00 PM | 5 days ago |
| SMA: Bearish | Oct 26, 11:20 AM | 5 days ago |
| SMA: Bullish | Oct 26, 11:15 AM | 5 days ago |
| SMA: Bearish | Oct 26, 11:05 AM | 5 days ago |
| SMA: Bullish | Oct 26, 10:55 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:40 AM | 5 days ago |
| SMA: Bullish | Oct 26, 10:20 AM | 6 days ago |
News
1 day ago seekingalpha.com
Novartis: Q3 2026 Earnings Confirm 'Hold' Recommendation Based On Balanced Approach
Novartis is rated Hold, with a 12-month price target of $141.81, implying a 12.0% downside from the current share price. My model indicates near-term pressure on selected products, while projected…
1 day ago zacks.com
All You Need to Know About Novartis (NVS) Rating Upgrade to Buy
Novartis (NVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
1 day ago zacks.com
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
2 days ago cnbc.com
A pharma giant is moving past one patent cliff — but another is already looming
Novartis CEO Vas Narasimhan told CNBC on Tuesday that its drug remibrutinib could become "one of our largest medicines in history." But analysts slashed the peak sales forecast for the drug after a…
3 days ago seekingalpha.com
Novartis AG (NVS) Q3 2026 Earnings Call Transcript
Novartis AG ( NVS ) Q3 2026 Earnings Call October 27, 2026 8:00 AM EDT Company Participants Isabella Zinck - Investor Relations Manager Vasant Narasimhan - Chief Executive Officer Mukul Mehta - Chief…
4 days ago zacks.com
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
-
4 days ago benzinga.com
Monte Rosa To Receive $37.5M Milestone Payment From Novartis Following Initiation Of Second Phase 2 Trial Of MRT-6160 In Psoriatic Arthritis
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that its collaborator Novartis has…
-
4 days ago benzinga.com
Monte Rosa Says Its Collaborator Novartis Initiates Second Phase 2 Clinical Study For VAV1-Directed MGD MRT-6160 In People Living With Active Moderate To Severe Psoriatic Arthritis
Phase 2 study to be conducted in participants with active moderate to severe psoriatic arthritisNovartis conducting study under global exclusive development and commercialization license agreement…
4 days ago marketbeat.com
What Novartis (NVS) Said on Its Q3 Earnings Call
Novartis NYSE: NVS reported third-quarter sales growth and margin expansion, supported by demand for priority medicines and productivity initiatives, while raising its full-year outlook for core…
4 days ago zacks.com
4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential
LLY, NVS, JNJ and ABBV offer arthritis drug growth potential through rising sales, regulatory approvals and clinical advances across inflammatory joint diseases.
4 days ago zacks.com
NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss
Novartis beats Q3 earnings estimates and raises its 2026 operating income outlook as Kisqali, Kesimpta and Scemblix offset generic competition.
4 days ago benzinga.com
Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9 Billion Avidity Hit
Novartis AG (NYSE:NVS) reported mixed third-quarter earnings on Tuesday as the prized Avidity Biosciences deal worth $12 billion cost the company an estimated $1.9 billion in impairment charges,…
4 days ago benzinga.com
Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9 Billion Avidity Hit
Novartis beat Q3 adjusted earnings estimates despite a $1.9 billion Avidity impairment charge, lifted by strong sales of Kisqali, Kesimpta, and revised guidance.
5 days ago zacks.com
Novartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
5 days ago benzinga.com
Novartis Q3 2026 Earnings Call Transcript
Novartis (NYSE:NVS) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
5 days ago investors.com
Novartis Hikes Income Forecast, But There Were Caveats Within Its Report
Novartis stock rose slightly early Tuesday on strong third-quarter income, but the company's biggest moneymaker, Kisqali, fell short.
5 days ago benzinga.com
Stock Market Today: Dow Jones, S&P 500, Nasdaq 10 Futures Gain as Fed Begins Its Two-Day Meet— Novartis, HSBC, Welltower in Focus (UPDATED)
U.S. stock futures were mixed on Tuesday, as the Dow Jones, S&P 500, and Nasdaq 100 indices moved in different directions.
-
5 days ago benzinga.com
Novartis Keeps FY 2026 Net Sales Growth At Low Single-Digit, Raises Core Operating Income Outlook To In Line To Low Single-Digit Growth
Full-year 2026 guidance raised for core operating income o Net sales expected to grow low single-digit (unchanged) o Core operating income expected to be in line to grow low single-digit (from…
-
5 days ago benzinga.com
Novartis Q3 Adj. EPS $2.46 Beats $2.27 Estimate, Sales $14.522B Miss $14.582B Estimate
Novartis (NYSE:NVS) reported quarterly earnings of $2.46 per share which beat the analyst consensus estimate of $2.27 by 8.37 percent. This is a 9.33 percent increase over earnings of $2.25 per share…
5 days ago wsj.com
Novartis Raises Guidance Despite Trial Setbacks Hitting Profit
The Swiss drugmaker cited solid sales growth and productivity gains, even as recent clinical-trial setbacks hit its bottom line in the third quarter.
5 days ago benzinga.com
Stock Market: Will S&P 500 Open Up or Down Today?
Futures edge higher as earnings, the Fed meeting and Anthropic IPO drive markets; oil falls as traders see 67% odds of an S&P 500 up open.
5 days ago benzinga.com
Visa, Coca-Cola On Deck Tuesday As Payments Growth, Global Demand Face Test
Visa is Tuesday’s most material report, with investors looking for continued payments growth after a strong run in the stock. Coca-Cola, HSBC Holdings, Novartis, Boeing and S&P Global report before…
1 week ago defenseworld.net
Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity
Novartis (NYSE: NVS) presented Phase III results for remibrutinib in relapsing multiple sclerosis, reporting that the oral Bruton's tyrosine kinase inhibitor reduced relapse rates and MRI lesion…
3 weeks ago benzinga.com
FDA Greenslights Novartis's Rhapsido as First Treatment for Chronic Friction Hives
FDA approves Novartis’s Rhapsido for symptomatic dermographism, marking the first treatment for adults with friction-triggered chronic hives
-
3 weeks ago benzinga.com
Novartis Receives FDA Approval For Rhapsido To Treat Symptomatic Dermographism
https://www.novartis.com/news/media-releases/novartis-rhapsido-remibrutinib-receives-fda-approval-first-treatment-symptomatic-dermographism-sd-expanding-its-use-beyond-chronic-spontaneous-urticaria-cs…
1 month ago benzinga.com
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease
Celldex posts positive Phase 3 data for barzolvolimab to treat chronic spontaneous urticaria. The company plans a 2027 FDA submission.
1 month ago benzinga.com
Novartis Halts Experimental ALS Drug Trial but Acquires Brain Delivery Platform
Novartis halted its mid-stage ALS drug trial for VHB937 but exercised a $125 million option to acquire Sironax's brain delivery platform.
1 month ago benzinga.com
Top Investor Urges Novartis for Stronger Acquisition Oversight After M&A and Trial Setbacks
Artisan Partners calls on Novartis to revamp board governance and acquisition oversight following sharp stock declines after trial setbacks.
-
1 month ago benzinga.com
HSBC Upgrades Novartis to Hold, Raises Price Target to $136
HSBC analyst Rajesh Kumar upgrades Novartis (NYSE:NVS) from Reduce to Hold and raises the price target from $123 to $136.
1 month ago benzinga.com
Nvidia, FAA Join Palantir’s AI Expansion as Cyber Push Takes Off
Palantir expands its AI footprint via new enterprise deployments, a free cybersecurity initiative, and an upgraded sovereign AI partnership with Fujitsu.
1 month ago benzinga.com
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower
Sarepta Therapeutics shares react to Novartis Phase 3 trial results in DM1 while Sarepta progresses its SRP-1003 RNA therapy clinical trials.
1 month ago benzinga.com
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling
Dyne Therapeutics stock sinks on Novartis' failed Phase 3 myotonic dystrophy study, even as Dyne prepares new trial data presentations.
1 month ago benzinga.com
QUICK SPARK: Amgen Stock Eyes Worst Day Since October 2000
Amgen sank 9.8% Tuesday after Novartis' pelacarsen missed its Phase 3 endpoint, casting doubt on rival Lp(a) drug olpasiran.
1 month ago benzinga.com
S&P 500, Nasdaq Slip as $98 Brent Reignites Inflation Fears: Stock Market Today
Crude near $98 pushes the 10-year Treasury yield above 4.8% for the first time since 2023, hammering the Dow as traders price a Fed rate hike next week.
1 month ago benzinga.com
What's Going On With Amgen Stock Tuesday?
AMGN stock dips 9% after rival drug trial misses goal. Discover Amgen key support levels, technical outlook, and analyst price targets
-
1 month ago benzinga.com
Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings
U.S. stocks fell Tuesday as health care lagged, while energy gained. ABM beat estimates; oil rose, and several biotech shares surged or plunged.
1 month ago benzinga.com
Why Is Eli Lilly Stock Falling Tuesday?
Eli Lilly (LLY) falls 2% amid a broader healthcare sell-off. Key support levels, technical breakdown, and market outlook analyzed.
1 month ago benzinga.com
Stock Market Today: S&P 500, Dow, Nasdaq 100 Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction— ASML, NVS, CASY in Focus (UPDATED)
Stock Market Today: S&P 500, Dow Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction— ASML, NVS, CASY in Focus
1 month ago benzinga.com
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.
1 month ago benzinga.com
Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners
Novartis stock falls following Phase 3 clinical trial failures for del-desiran and pelacarsen, impacting Ionis and Royalty Pharma shares.
-
1 month ago benzinga.com
Market-Moving News for September 8th
NVS: -13% | Novartis shares are trading lower after the company announced the pelacarsen phase III Lp(a)HORIZON trial did not meet its primary endpoint. IONS: -13% | Ionis Pharmaceuticals shares are…
1 month ago benzinga.com
Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
iSpecimen surged 27.9% premarket on a $4.5M Foldlab AI asset deal; CEA Industries led gainers, while Focus Universal plunged 51.2%.
1 month ago benzinga.com
United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday
Stocks in focus: UNFI and ABM earnings, Novartis trial miss, Co-Diagnostics CFO change, and Casey’s earnings expected.
1 month ago benzinga.com
Brent Jumps to $97, German AfD Party Wins Big: Stock Market Today
Europe closed mixed as the AfD's Saxony-Anhalt landslide and $97 Brent lifted bond yields, and Wall Street sat out Labor Day.
-
1 month ago benzinga.com
Novartis’ Pelacarsen Phase III Lp(a)HORIZON Trial Fails Primary Cardiovascular Endpoint; Lowered Lp(a) Levels But Did Not Reduce CV Events
Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not meet its primary endpoint of reducing the risk of cardiovascular events,…
1 month ago benzinga.com
A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths
Novartis and Bristol Myers pause CAR-T autoimmune trials after patient deaths and severe side effects spark safety concerns.
2 months ago benzinga.com
The Multiple Sclerosis Drug Race Just Got Hotter After Novartis’ Phase 3 Win
Novartis stock spikes 5% on positive Phase 3 REMODEL trial results for relapsing MS drug remibrutinib with no liver safety signals.
2 months ago benzinga.com
Yext Posts Upbeat Q2 Earnings, Joins Fervo Energy, MiniMed Group And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Nasdaq Composite falling around 1% on Tuesday. Shares of Yext Inc (NYSE:YEXT) rose sharply after the company reported better-than-expected second-quarter earnings.…
2 months ago benzinga.com
Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says
William Blair initiates Enliven Therapeutics (ELVN) with Outperform, highlighting ELVN-001's strong CML trial data & $8.8B market potential.
2 months ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…